<Anchor> The



US Food and Drug Administration and the FDA have announced that it is safe and effective for Johnson & Johnson's COVID-19 vaccine.

It is expected to be approved soon, and although it is less effective than other vaccines, it is expected that it will become a'game changer' because it can only be hit once and is easy to store.



This is Kim Yoon-soo, correspondent in Washington.



<Reporter> The



FDA of the US Food and Drug Administration found that Johnson & Johnson's COVID-19 vaccine phase 3 clinical trial showed 72% in the US and 64% in South Africa.



The preventive effect is lower than that of Pfizer and Moder or vaccines, which are more than 90%, but exceeds the FDA's lowest limit of 50%.



In particular, it differs from previously approved vaccines in that clinical trials were conducted after the mutant virus spread.



The effectiveness of preventing severe COVID-19 has risen significantly to 86% in the US and 82% in South Africa.



No cases of vaccinating deaths or serious allergic reactions have been reported.



[Gupta/CNN medical reporter: What is the goal of the vaccine?

It prevents severe infections, hospitalization and death.

In this regard, this vaccine seems to be quite effective.] The



US FDA is planning to hold an advisory meeting on the 26th to discuss whether to recommend the use of the vaccine.



Johnson & Johnson plans to supply 100 million servings to the U.S. by June, and 1 billion servings to the world by the end of this year when emergency use is approved.



[Giants/U.S. White House Corona 19 Coordinator: If urgent use is approved, it is expected that 3 to 4 million doses of Johnson & Johnson vaccine will be allocated by next week.]



Unlike existing vaccines, this vaccine can be given only once. It is expected to be a'game changer' as it can be stored for three months at a refrigerated temperature.